UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
24.12
+0.35 (1.47%)
At close: Apr 28, 2026, 4:00 PM EDT
24.12
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:29 PM EDT
UroGen Pharma Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for UroGen Pharma stock have an average target of 29.29, with a low estimate of 3.00 and a high estimate of 47. The average target predicts an increase of 21.43% from the current stock price of 24.12.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for UroGen Pharma stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $33 | Strong Buy | Maintains | $33 | +36.82% | Mar 31, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $33 | Strong Buy | Maintains | $33 | +36.82% | Mar 2, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $33 | Strong Buy | Maintains | $33 | +36.82% | Jan 23, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $33 | Strong Buy | Maintains | $33 | +36.82% | Jan 5, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +65.84% | Oct 27, 2025 |
Financial Forecast
Revenue This Year
251.51M
from 109.79M
Increased by 129.09%
Revenue Next Year
429.97M
from 251.51M
Increased by 70.96%
EPS This Year
-1.19
from -3.19
EPS Next Year
1.25
from -1.19
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 306.9M | 601.2M | ||||||
| Avg | 251.5M | 430.0M | ||||||
| Low | 214.9M | 323.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 179.6% | 139.0% | ||||||
| Avg | 129.1% | 71.0% | ||||||
| Low | 95.7% | 28.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.25 | 3.26 | ||||||
| Avg | -1.19 | 1.25 | ||||||
| Low | -1.95 | 0.44 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.